PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Guangzhou Science and Technology Program key projects
Sun Yat-sen University Cancer Center
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Zusheng Xu, Peng Sun, Hong Cen, Xuekui Gu et al.
Citations
1 citations
Journal
Cancer Cell International
Topics
Lymphoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
1.47
article
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Sun Yat-sen University (CN), Zhejiang Cancer Hospital (CN), First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN), Zhujiang Hospital (CN), Sun Yat-sen University Cancer Center (CN), Tumor Hospital of Guangxi Medical University (CN), First Affiliated Hospital Zhejiang University (CN), Southern Medical University (CN)
Funders
National Natural Science Foundation of China, Sun Yat-sen University, National Science and Technology Major Project, Guangzhou Science and Technology Program key projects, Sun Yat-sen University Cancer Center
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial — Zusheng Xu, Peng Sun, et al. · Cancer Cell International (2025) | TGRS Research Map | TGRS